Moreover, the recent inclusion of immunotherapy as part of the standard of care for the treatment of BRAF-mutant melanoma will be instrumental in not only understanding the effect of ERK inhibition on the tumor-immune microenvironment, but also in determining the impact of the combination of anti-PD-1/PD-L1 therapy with MAPK inhibition. This evidence concerns the gene BRAF and neoplasm.